drugset / Trial / NCT05601323

A Study of Suizenji in Patients With Unresectable Pancreatic Cancer

NCT05601323

Active not recruiting 90 enrolled SONIRE Therapeutics Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of standard chemotherapy with or without a novel High Intensity Focused Ultrasound system (Code: Suizenji) in patients with unresectable pancreatic cancer who are refractory or intolerant to first-line chemotherapy.

Timeline

Start
2023-01-31
Primary completion
2027-05-31
Completion
2027-05-31

Drugs

EvaluationDrugModalityDoseRoute
Background Gemcitabine Small molecule
Background Irinotecan Small molecule
Background Levoleucovorin Unknown
Background Oxaliplatin Small molecule
Background Paclitaxel Small molecule
Background fluorouracil Small molecule

Indications